# Nutrigenomics Market

> Nutrigenomics Market Research Report By Application (Personalized Nutrition, Disease Prevention, Health Optimization, Fitness and Athletic Performance), By End Use (Healthcare, Dietary Supplements, Food Beverage, Pharmaceuticals), By Product Type (Genetic Testing Kits, Bioinformatics Tools, Nutritional Analysis Software), By Technology (DNA Sequencing, Microarray Analysis, Polymerase Chain Reaction) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025-2035
- **CAGR:** 16.4%
- **2025:** USD 0.86 Billion (2025)
- **2035:** USD 3.89 Billion (2035)
- **Key Players:** Nutrigenomix Inc., Prenetics (DNAfit), 23andMe, Viome Life Sciences, Metagenics, DSM-Firmenich, Nestlé Health Science, BASF Human Nutrition

**Report ID:** MRFR/Pharma/2692-CR · **Pages:** 94 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** June 30, 2026

**URL:** https://www.marketresearchfuture.com/reports/nutrigenomics-market-4009

---

## Market Summary

Global Nutrigenomics Market Size was valued at USD 0.68 Billion in 2024 & the market is projected to grow from USD 0.799 Billion in 2025 to USD 4.008 Billion by 2035, registering a CAGR of 17.50% during the forecast period 2025–2035. North America led the market with over 45% share, generating around USD 0.3 Billion in revenue.
 
The growing demand for personalized nutrition based on individual genetic profiles is a major growth driver for the Nutrigenomics Market. Increasing consumer awareness of preventive healthcare, coupled with advances in genetic testing technologies, is encouraging the adoption of tailored dietary recommendations to improve long-term health outcomes.
 
According to the WHO, noncommunicable diseases account for approximately 41 million deaths annually, representing 74% of global deaths, increasing interest in personalized nutrition approaches that help individuals manage health risks through genetics-informed dietary interventions.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Collapsing sequencing costs | ~25% | Global | Short-term (≤2 yr) | [1] |
| Preventive healthcare policy mandates | ~20% | North America, Europe | Medium-term (2–4 yr) | [2] |
| AI-powered nutrition algorithms | ~18% | Global | Medium-term (2–4 yr) | [11] |
| Microbiome science integration | ~15% | North America, Asia-Pacific | Long-term (≥4 yr) | [10] |
| Corporate wellness & insurer incentives | ~10% | North America, Europe | Short-term (≤2 yr) | [9] |
| Mobile-first DTC platforms in emerging markets | ~8% | Asia-Pacific, South America | Medium-term (2–4 yr) | [5] |
| Regulatory harmonization (EU MDR, FDA LDT) | ~4% | Europe, North America | Long-term (≥4 yr) | [6] |

### Collapsing Sequencing Costs

Since the Human Genome Project era, the price of [whole-genome sequencing](https://www.marketresearchfuture.com/reports/gene-sequencing-market-21841) has dropped by over 99.9%. An estimated price for a consumer-grade test is roughly USD 600 in 2025 [[1]](https://genome.gov). This price compression changes nutrigenomics from a clinical specialty service to a mass-market consumer product. Illumina’s NovaSeq X series and Element Biosciences’ AVITI are driving per-genome costs down to around USD 100, and analysts expect this to unleash uptake among price-sensitive groups in South and Southeast Asia.

### Preventive Healthcare Policy Mandates

Government healthcare budgets globally are pivoting toward prevention. The UK's NHS Long Term Plan allocates GBP 4.5 billion toward genomic medicine infrastructure through 2028 [[2]](https://hhs.gov). These policy frameworks create direct reimbursement pathways for the Nutrigenomics Market.

### AI-Powered Nutrition Algorithms

Machine-learning platforms that integrate polygenic risk scores with dietary recall data can generate personalized meal plans in under 60 seconds. This accelerates adoption among healthcare providers operating within the Nutrigenomics Market.

### Microbiome Science Integration

By overlaying 16S rRNA and shotgun metagenomic sequencing on top of existing DNA genotyping, we construct a dual-data personalization engine. The American Gut Project, with over 30,000 participant samples, has given the training datasets for commercial microbiome-nutrigenomic solutions [[10]](https://asm.org). Companies in the Nutrigenomics Market are progressively integrating gut-health profiling with genetic kits to generate greater average order values.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Consumer data privacy concerns | ~–3.5% | Global | Ongoing | [13] |
| Limited clinical validation for some claims | ~–2.8% | Global | Medium-term | [14] |
| Regulatory fragmentation across jurisdictions | ~–2.2% | Europe, Asia-Pacific | Long-term | [6] |
| High out-of-pocket cost in developing markets | ~–1.5% | South America, MEA | Medium-term | [5] |
| Physician skepticism and low referral rates | ~–1.0% | Global | Short-term | [15] |

### Consumer Data Privacy Concerns

Genetic data is among the most sensitive personal information a consumer can share. The absence of a unified global standard — GDPR applies in Europe, GINA covers employment discrimination in the U.S., and many Asian markets lack dedicated genetic-data legislation — creates consumer hesitation [[13]](https://pewresearch.org).

### Limited Clinical Validation

There is strong evidence for some gene-diet interactions (e.g., MTHFR variations and folate metabolism), although many commercial nutrigenomic recommendations are derived from genome-wide association studies with small effect sizes [[14]](https://academic.oup.com). The FDA has not developed a formal approval process for nutrigenomic dietary recommendations, leaving the Nutrigenomics Market open to challenges to its credibility by advocates of evidence-based medicine.

### Regulatory Fragmentation

The European Union’s In Vitro Diagnostic Regulation (IVDR), which came into force in May 2022, has very different classification standards for genetic tests than the FDA’s Laboratory Developed Test framework [[6]](https://ec.europa.eu). Companies moving across regions have to confront overlapping compliance standards, resulting in increased market-entry costs and hence slowing down worldwide progress within the Nutrigenomics Market.

## Opportunities

## Nutrigenomics Market Opportunities

### Employer-Sponsored Precision Wellness Programs

In the United States, large firms spend an average of USD 15,000 a year on healthcare per employee [[9]](https://kff.org). Nutrigenomic screening – less than USD 300 per employee — provides an attractive ROI in terms of identifying metabolic risk profiles early and customizing dietary interventions. Corporate contracts are a high-volume recurring-revenue channel for Nutrigenomics Market participants.

### Subscription-Based Personalized Supplement Delivery

Pairing genetic insights with monthly subscription boxes of custom-formulated supplements creates a sticky business model with 70%+ gross margins. Companies that own both the testing platform and the fulfillment pipeline can capture lifetime customer value exceeding USD 2,000. This vertical integration opportunity is reshaping competitive dynamics in the Nutrigenomics Market.

### Emerging-Market Mobile Health Platforms

India's Ayushman Bharat Digital Mission and China's Healthy China 2030 initiative are digitizing healthcare delivery at national scale [[5]](https://worldbank.org). Mobile-first nutrigenomics platforms that offer affordable saliva-based genotyping paired with vernacular-language dietary guidance can tap populations of over 2.8 billion across these two markets alone.

### Pharmacogenomic-Nutrition Convergence

Integrating drug-gene interaction data with nutrient-gene models creates a unified precision-health platform. Patients on statins, for example, can receive simultaneous guidance on CoQ10 supplementation based on their SLCO1B1 genotype [[12]](https://sciencedirect.com). This convergence expands the addressable Nutrigenomics Market beyond wellness into clinical pharmacy.

### Data Monetization Through Anonymized Cohort Insights

Aggregated, de-identified nutrigenomic datasets hold significant value for pharmaceutical R&D, food product development, and population-health research. Companies with large genotyped consumer bases can license anonymized insights as a secondary revenue stream, diversifying beyond test-kit sales.

## Future Outlook

## Nutrigenomics Market Future Outlook

### AI and Multi-Omic Integration

By 2030, standalone genotyping will give way to multi-omic platforms that simultaneously analyze genomic, proteomic, metabolomic, and microbiome data. The global [AI-in-genomics](https://www.marketresearchfuture.com/reports/ai-genomics-market-31278) segment is projected to exceed USD 6.5 billion by 2030 [[11]](https://nature.com), and nutrigenomics companies that embed deep-learning engines into their recommendation workflows will capture disproportionate market share within the Nutrigenomics Market.

### Platform Economics and Vertical Integration

The Nutrigenomics Market is shifting toward vertically integrated platforms that own the full stack — from saliva-collection kits to AI-driven dietary plans to subscription supplement fulfillment. Platform models reduce customer acquisition costs by 40–60% compared to standalone testing services, and recurring-revenue subscriptions stabilize cash flows against test-volume cyclicality.

### Regulatory Maturation and Clinical Standardization

The FDA's evolving framework for Laboratory Developed Tests, finalized by 2024, imposes consistent accuracy and validity requirements on nutrigenomic assays sold in the U.S. [[6]](https://ec.europa.eu). The EU's European Health Data Space regulation, targeted for implementation by 2029, will standardize cross-border genetic data sharing, enabling pan-European Nutrigenomics Market scalability [[6]](https://ec.europa.eu).

### ESG, Population Health, and Preventive ROI

Public-health systems globally face unsustainable chronic-disease spending — the WHO estimates that the global macroeconomic losses from the four primary non-communicable diseases would hit USD 30 trillion by 2030, attributing the separate USD 17 trillion metric specifically to the global cumulative losses from mental health conditions. Gene-guided dietary intervention offers a scalable, evidence-based prevention tool. ESG-focused investors increasingly view the Nutrigenomics Market as aligned with UN Sustainable Development Goal 3 (Good Health and Well-Being), channeling capital toward companies demonstrating measurable health-outcome improvements.

## Segment Insights

## Nutrigenomics Market Segmentation

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Obesity | 37.9% share (2025) | Global obesity epidemic, gene-guided weight management |
| Cancer | 13.6% CAGR (2026–2035) | Oncology nutrition integration, epigenomic research |
| Cardiovascular Diseases | USD 0.18 Billion (2025) | Lipid metabolism gene variants, statin-nutrient interactions |
| Other Applications | 11.8% CAGR (2026–2035) | Diabetes, neurological conditions, sports nutrition |

Obesity dominates the Nutrigenomics Market application landscape. With over 890 million adults classified as obese globally by the WHO in 2024 [[23]](https://who.int), demand for genetically tailored dietary interventions continues to outpace other categories. Companies such as Nutrigenomix and DNAfit have built their core commercial propositions around weight-management gene panels that map FTO, MC4R, and ADRB2 variants to macronutrient recommendations.

Cancer-related nutrigenomics is the fastest-expanding application within the Nutrigenomics Market. Emerging research links specific polymorphisms (e.g., MTHFR C677T) to folate metabolism pathways implicated in colorectal cancer risk, creating clinical demand for gene-informed dietary surveillance [[14]](https://academic.oup.com).

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Vitamins & Minerals | 33.1% share (2025) | Established category, broad retail access |
| Probiotics & Prebiotics | 13.2% CAGR (2026–2035) | Microbiome science, gut-brain axis research |
| Diagnostic Kits & Reagents | USD 0.22 Billion (2025) | Clinical-grade genotyping demand |

Vitamins and minerals remain the revenue backbone of the Nutrigenomics Market product mix, benefiting from consumer trust in established supplement categories and straightforward regulatory pathways. Probiotics and prebiotics represent the growth frontier, propelled by mounting evidence that strain-specific supplementation guided by individual microbiome composition delivers superior health outcomes compared to generic formulations [[10]](https://asm.org).

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Direct-to-Consumer | 51.2% share (2025) | At-home kit convenience, digital marketing reach |
| Hospitals & Clinics | 14.9% CAGR (2026–2035) | Clinical integration and physician adoption |
| Research Institutes | USD 0.09 Billion (2025) | Grant-funded genomics studies |

The direct-to-consumer channel commands the majority of the Nutrigenomics Market, as consumers increasingly bypass traditional healthcare gatekeepers to access genetic insights directly. Online marketing, influencer partnerships, and streamlined kit-to-result workflows have reduced the DTC customer journey to under 21 days in leading markets.

### By Distribution Channel

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Online Platforms | 56.0% share (2025) | E-commerce growth, subscription models |
| Offline (Retail, Clinics) | 10.8% CAGR (2026–2035) | Pharmacy partnerships, in-clinic testing |

Online distribution dominates the Nutrigenomics Market, with e-commerce platforms and brand-direct websites accounting for the majority of consumer test-kit sales. The channel's strength reflects the inherently digital nature of the product: consumers order kits online, mail saliva samples, and receive results via app or web portal.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 42.0% share (2025) | DTC genetic testing, insurer partnerships, clinical integration |
| Europe | 28.5% share (2025) | Horizon Europe precision nutrition grants, IVDR compliance |
| Asia-Pacific | 14.5% CAGR (2026–2035) | Mobile health platforms, middle-class wellness spending |
| South America | USD 0.05 Billion (2025) | Public-health genomics pilots, telemedicine expansion |
| Middle East & Africa | 4.5% share (2025) | Government health-vision programs, medical tourism |
| Total | USD 0.86 Billion (2025) | — |

The Nutrigenomics Market exhibits a distinct geographic hierarchy, with North America dominating revenue contribution and Asia-Pacific leading growth velocity. Regional dynamics reflect differences in regulatory infrastructure, consumer genomics literacy, healthcare spending patterns, and [digital health](https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636) adoption.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 74.5% of regional share | Mature DTC ecosystem, ACA preventive mandates [2] |
| Canada | 15.8% CAGR | Provincial health innovation funds [16] |
| Mexico | USD 0.02 Billion | Growing middle-class wellness awareness [5] |

The United States anchors the Nutrigenomics Market in North America, driven by widespread consumer familiarity with at-home genetic kits and a reimbursement environment that increasingly covers genetic counseling services. Canada's genomics strategy, backed by Genome Canada's CAD 280 million investment pipeline, is catalyzing academic-commercial partnerships that translate research into commercial products [[16]](https://genomecanada.ca).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.2% of regional share | Strong pharma-nutrition crossover R&D [6] |
| UK | 14.8% CAGR | NHS Genomic Medicine Service expansion [2] |
| France | USD 0.04 Billion | National nutrition and health program (PNNS) [17] |
| Italy | 10.5% of regional share | Mediterranean-diet genomics research tradition [14] |
| Spain | 12.6% CAGR | Biobanking infrastructure investment [18] |
| Nordic Countries | USD 0.03 Billion | High digital-health penetration |
| Russia | 4.2% of regional share | Emerging private-sector genomics labs |
| Rest of Europe | 13.8% CAGR | EU cross-border health data regulation [6] |

Europe's Nutrigenomics Market benefits from the EU's commitment to precision medicine through Horizon Europe, which earmarks over EUR 8.2 billion for health cluster research during 2021–2027 [[6]](https://ec.europa.eu). The UK's NHS Genomic Medicine Service, currently sequencing 300,000 genomes annually, provides a clinical infrastructure that nutrigenomics companies can leverage for validation studies [[2]](https://hhs.gov).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 32.8% of regional share | Healthy China 2030 policy, BGI ecosystem [5] |
| India | 17.2% CAGR | Ayushman Bharat digital health stack [5] |
| Japan | USD 0.03 Billion | Aging-population nutrition innovation [19] |
| South Korea | 15.1% CAGR | K-Bio strategy and genomics investment [20] |
| ASEAN | 13.8% of regional share | Mobile-first health platforms [5] |
| Rest of Asia-Pacific | USD 0.01 Billion | Early-stage market development |

Asia-Pacific represents the fastest-growing frontier for the Nutrigenomics Market. China's BGI Genomics operates the world's largest sequencing capacity, enabling low-cost consumer genomics, while India's rapidly expanding digital health infrastructure connects rural populations to telehealth-based nutrition guidance [[5]](https://worldbank.org).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.0% of regional share | FAPESP genomics research grants [21] |
| Argentina | 14.2% CAGR | University-led precision nutrition pilots |
| Rest of South America | USD 0.01 Billion | Early adoption phase |

Brazil dominates the South American Nutrigenomics Market, supported by the country's advanced biomedical research infrastructure and FAPESP-funded genomics programs [[21]](https://fapesp.br). Argentina's public university system is producing early clinical evidence linking regional dietary patterns to genetic predispositions.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 30.5% of regional share | Vision 2030 health-sector investment [22] |
| UAE | 16.0% CAGR | Medical tourism and premium wellness clinics [22] |
| South Africa | USD 0.005 Billion | Academic genomics research hubs |
| Egypt | 12.5% CAGR | Population-scale health digitization |
| Rest of MEA | 28.0% of regional share | International aid-funded health programs |

Saudi Arabia's Vision 2030 healthcare transformation and the UAE's status as a regional medical-tourism hub are positioning the Gulf states as the primary growth engines for the Nutrigenomics Market in the MEA region [[22]](https://vision2030.gov.sa).

## Competitive Benchmarking

## Competitive Benchmarking

The Nutrigenomics Market exhibits medium concentration, with the top five players holding an estimated 35–40% combined revenue share. The HHI index sits in the 800–1,200 range, indicating a moderately fragmented landscape where DTC genetic testing companies compete alongside legacy supplement manufacturers and emerging AI-driven platforms. Strategic differentiation centers on three axes: breadth of genetic panel coverage, quality of personalized recommendation algorithms, and control over downstream supplement fulfillment.

| Company | Est. Revenue Share Range | Key Offerings for Nutrigenomics Market | Strategic Positioning |
| --- | --- | --- | --- |
| Nutrigenomix Inc. | ~7–10% | Clinician-grade 70+ gene panel, practitioner network | Clinical channel leader, research-validated panels |
| Prenetics (DNAfit) | ~6–9% | Consumer genetic kits, CircleDNA platform | DTC scale, Asia-Pacific footprint |
| 23andMe | ~5–8% | Health + ancestry reports, pharmacogenomics add-ons | Massive consumer database, brand recognition |
| Viome Life Sciences | ~4–7% | mRNA-based gut-health tests, precision supplements | Microbiome-first approach, subscription model |
| Metagenics | ~4–6% | Practitioner-dispensed supplements, genetic guidance tools | Clinical nutrition heritage, B2B channel strength |
| DSM-Firmenich | ~3–5% | Personalized nutrition ingredients, B2B formulation platforms | Ingredients giant, upstream supply position |
| Nestlé Health Science | ~3–5% | Consumer health brands, nutrigenomic R&D partnerships | Global distribution, brand trust |
| BASF Human Nutrition | ~2–4% | Vitamin and omega-3 ingredient supply, co-development | Upstream ingredient positioning |
| GenoPalate | ~2–3% | DNA-based food recommendations, consumer app | Affordable DTC entry point |
| Orig3n | ~1–3% | Fitness and nutrition gene panels, retail kits | Mass-market retail distribution |

## Recent News & Developments

## Recent News & Developments

- [Viome Life Sciences](https://www.viome.com/) (August 2023): Secured USD 86 million in Series C funding to scale its mRNA-based precision supplement line across North America and Asia-Pacific [[10]](https://asm.org).
- 23andMe (November 2024): Formally expanded its premium digital subscription ecosystems by incorporating advanced, multi-condition polygenic risk scores (PRS) to provide users with proactive, clinical-grade predisposition reports for major hereditary cancers, including detailed tracking for breast, colorectal, and prostate oncological risk states.

- FDA (May 2024): Published its highly anticipated Final Rule governing Laboratory Developed Tests (LDTs), amending regulations to state that in vitro diagnostics manufactured by laboratories are medical devices under the Federal Food, Drug, and Cosmetic Act, establishing a strict four-year phased enforcement roadmap for data validation.
- Nestlé Health Science (August 2023): Solidified its leading vertical position within full-stack personalized nutrition ecosystems by driving international distribution networks for its vertically integrated Persona platform, utilizing automated data algorithms to compile consumer lifestyle indicators into targeted monthly subscription supplement boxes.

## Report Scope

## Nutrigenomics Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Nutrigenomics Market, covering applications, products, end users, distribution channels, and five geographic regions |
| Study Period | 2021–2035 |
| CAGR (2026–2035) | 16.4% |
| Base Year Market Size | USD 0.86 Billion (2025) |
| Forecast Endpoint | USD 3.89 Billion (2035) |
| Fastest Growing Segment | Probiotics & Prebiotics (by product); Cancer (by application); Asia-Pacific (by region) |
| Companies Profiled | 10 (Nutrigenomix, Prenetics, 23andMe, Viome, Metagenics, DSM-Firmenich, Nestlé Health Science, BASF, GenoPalate, Orig3n) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do reimbursement policies affect the commercial viability of nutrigenomic testing?**
A: Reimbursement remains limited to genetic counseling in most U.S. commercial plans, though Medicare Advantage pilots are testing coverage for metabolic-risk gene panels [2]. Broader payer adoption would significantly lower out-of-pocket costs and accelerate volume growth.

**Q: What distinguishes clinical-grade from consumer-grade nutrigenomic panels?**
A: Clinical panels analyze 50–70+ validated gene variants under CLIA-certified lab protocols, while consumer kits typically cover 20–30 markers with lower analytical stringency [14]. Regulatory oversight and report interpretation by licensed practitioners set the clinical tier apart.

**Q: How are nutrigenomics companies addressing genetic data portability?**
A: Leading platforms now offer downloadable raw-data files in VCF or CSV format, enabling consumers to transfer results between services [13]. Interoperability standards remain nascent, but the Global Alliance for Genomics and Health is developing data-sharing frameworks.

**Q: What role does epigenetics play in next-generation nutrigenomics?**
A: Epigenetic markers — particularly DNA methylation patterns — reveal how lifestyle and diet modify gene expression without altering the underlying sequence [12]. Integrating epigenomic data enables dynamic, time-sensitive dietary recommendations beyond static genotype analysis.

**Q: How do subscription models compare with one-time purchase models in profitability?**
A: Subscription platforms achieve 3–4x higher customer lifetime value than one-time kit sellers, driven by recurring supplement revenue and lower churn from personalized engagement loops [8]. Gross margins on subscriptions typically exceed 70%.

**Q: What cybersecurity standards apply to stored consumer genetic data?**
A: U.S. providers must comply with HIPAA when handling health-linked genetic data, while EU operators fall under GDPR's special-category data provisions [13]. SOC 2 Type II certification is emerging as the de facto industry benchmark for data-security posture.

**Q: How are food manufacturers integrating nutrigenomic insights into product development?**
A: CPG companies use aggregated, anonymized nutrigenomic datasets to identify population-level nutrient gaps and formulate targeted functional foods [12]. This data-driven approach reduces R&D cycle times and improves product-market fit for fortified and functional categories.

**Q: What is the current size of the nutrigenomics market?**
A: The nutrigenomics market reached USD 0.86 billion in 2025 and is projected to reach USD 3.89 billion by 2035.

**Q: What is the CAGR of the nutrigenomics market?**
A: The nutrigenomics market is projected to grow at a CAGR of 16.4% during the forecast period 2026–2035.

**Q: Which region leads the nutrigenomics market?**
A: North America holds the largest share at 42.0%, while Asia-Pacific is the fastest-growing region at 14.5% CAGR.

**Q: What is driving growth in the nutrigenomics market?**
A: Growth in the nutrigenomics market is primarily driven by rapidly falling genome-sequencing costs, a global policy shift toward preventive healthcare, and the integration of AI-powered nutrition algorithms that enable personalized, gene-guided dietary recommendations at scale.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/nutrigenomics-market-4009*